BiomX Inc Dossier - Source-backed chat

BiomX Inc

PHGENYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.13

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.85Price as of 10 Sep 2026

Data confidenceNot applicable

Market Cap $5M

Enterprise Value −$5K

Shares Outstanding 2.7M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BiomX Inc. has undergone a complete structural and operational transformation, abandoning its legacy clinical-stage phage therapy pipeline (following the discontinuation of BX004 and the insolvency of its core Israeli operating subsidiary, BiomX Ltd.) to pivot into the defense, security, and critical infrastructure technology sectors. Through the April 2026 acquisitions of Zorronet Ltd. (100% stake) and Dr. Frucht Systems Ltd. (60% stake), BiomX is attempting to establish a diversified portfolio of AI-powered command-and-control and LADAR-based detection systems. While these acquisitions open up high-growth defense markets, the company faces severe financial distress, a going-concern warning, and a strict September 25, 2027 deadline to regain compliance with NYSE American listing standards. Given the early-stage nature of the defense revenues, heavy concentration risks, and significant geopolitical exposure in Israel, a Hold recommendation is warranted until execution and financial stabilization are demonstrated.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to secure the necessary capital to fund its new defense operations, or the ongoing geopolitical conflict in Israel severely disrupts the operations of Zorronet and DFSL. Delays in product commercialization prevent the company from meeting NYSE American compliance standards, leading to a delisting from the exchange. Dilution from outstanding warrants and convertible notes further depresses the share price.

Base CaseCentral scenario

The company successfully integrates Zorronet and DFSL, leveraging their existing deployments with the Israel Defense Forces, Israel Railways, and major defense contractors like Elbit Systems. Internal funding of over $3 million for X Security & Defense drives initial product development, and the company manages to raise sufficient capital or restructure debt to satisfy the NYSE American stockholders' equity requirements by the September 2027 deadline. However, high integration costs, earnout obligations, and ongoing corporate overhead keep the company unprofitable in the near term.

Bull CaseUpside scenario

BiomX's successful strategic pivot from clinical-stage biotechnology to a high-growth defense, security, and first-response technology platform. This transition is anchored by the acquisition of Zorronet (an AI-powered autonomous command-and-control platform) and a controlling interest in DFSL (a high-accuracy LADAR-based counter-UAS and perimeter detection system). The bull case relies on the integration of these technologies to address the rapidly expanding global demand for counter-UAS, critical infrastructure protection, and real-time situational awareness, leveraging established relationships with major defense entities like the Israel Defense Forces, Elbit Systems, and Rafael.

Scenarios reflect our research view at the research date.

Key Investment Merits

Entry into high-growth defense and security markets, specifically targeting the $81 billion command-and-control and video analytics sectors by 2030.
Established operational footprint with mission-critical deployments at IDF bases, municipal security centers, and Israel Railways.
Reconstituted leadership team and advisory board, including prominent defense intelligence figures, providing deep sector expertise.

Key Investment Risks

Severe financial distress and going-concern uncertainty following the insolvency and deconsolidation of its core legacy subsidiary, BiomX Ltd.
Risk of delisting from the NYSE American exchange if the company fails to regain compliance with stockholders' equity standards by September 25, 2027.
High geographic and geopolitical concentration, with primary operations, subsidiaries, and key customers located in Israel.
Potential for substantial shareholder dilution from outstanding warrants, convertible notes, and performance-based earnout obligations.

Thesis Invalidation Triggers

Failure to maintain NYSE American listing or rejection of the compliance plan by NYSE Regulation.
Inability to secure additional financing to support the $3 million operational allocation for X Security & Defense.
Loss of key contracts or partnerships with major defense prime contractors like Elbit Systems.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.